


FIGURE 1






FIGURE 2

HBsAg levels (% of day -1)




FIGURE 3




FIGURE 4

Figure 5 shows the cumulative mean lesions for the three groups over the 78-day period. The Sham group (Group #1) shows a steady increase in lesions, reaching approximately 7.5 by day 78. The ISS 1 group (Group #2) shows a similar trend, reaching approximately 7.0 by day 78. The ISS 3 group (Group #3) shows a lower cumulative mean lesion score, reaching approximately 5.5 by day 78. The x-axis represents days post-injury, and the y-axis represents the cumulative mean lesion score.

FIGURE 5




Figure 6 shows the cumulative mean lesion days for four groups: Control oligo Day 21, Untreated, ISS Day 21 (single dose), and ACV (3x/day, 7 days). The y-axis represents Cumulative Mean Lesion Days (0 to 8), and the x-axis represents Days Post Inoculation (15 to 56). The Control oligo Day 21 group shows the highest cumulative mean lesion days, reaching approximately 7.5 by day 56. The Untreated group shows a similar trend, reaching approximately 7.0. The ISS Day 21 (single dose) group shows a lower cumulative mean lesion days, reaching approximately 5.0. The ACV (3x/day, 7 days) group shows the lowest cumulative mean lesion days, reaching approximately 3.0. A p-value of <0.001 is indicated for the comparison between the Control oligo Day 21 group and the ACV (3x/day, 7 days) group.




FIGURE 6





FIGURE 7








FIGURE 9

Figure 10: Mean  $\pm$  SEM of GMD in mm for Group C, treated and untreated sites, over 100 days after CRPV infection.




FIGURE 10